Phyllis J Goodman

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. pmc Moving a randomized clinical trial into an observational cohort
    Phyllis J Goodman
    SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Clin Trials 10:131-42. 2013
  2. ncbi request reprint The prostate cancer prevention trial: design, biases and interpretation of study results
    Phyllis J Goodman
    Southwest Oncology Group Statistical Center, Seattle, Washington 98109 1024, USA
    J Urol 175:2234-42. 2006
  3. pmc Transition of a clinical trial into translational research: the prostate cancer prevention trial experience
    Phyllis J Goodman
    Fred Hutchinson Cancer Research Center, Seattle WA 98109, USA
    Cancer Prev Res (Phila) 3:1523-33. 2010
  4. ncbi request reprint Implementation of the Prostate Cancer Prevention Trial (PCPT)
    Phyllis J Goodman
    Southwest Oncology Group Statistical Center, M S M3 C102, 1100 Fairview Avenue North, Box 19024, Seattle, WA 98109 1024, USA
    Control Clin Trials 25:203-22. 2004
  5. pmc Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach
    Mary W Redman
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Cancer Prev Res (Phila) 1:174-81. 2008
  6. ncbi request reprint Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial
    Zhihong Gong
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North M4 B402, Seattle, WA 98109 1024, USA
    Cancer Epidemiol Biomarkers Prev 15:1977-83. 2006
  7. pmc Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial
    Marian L Neuhouser
    Cancer Prevention Program, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Prostate 68:1477-86. 2008
  8. pmc Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial
    Alan R Kristal
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M4 B402, PO Box 19024, Seattle, WA 98109 1024, USA
    Am J Epidemiol 168:1416-24. 2008
  9. pmc Associations of serum sex steroid hormone and 5α-androstane-3α,17β-diol glucuronide concentrations with prostate cancer risk among men treated with finasteride
    Alan R Kristal
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Cancer Epidemiol Biomarkers Prev 21:1823-32. 2012
  10. pmc Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trial
    Marian L Neuhouser
    Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98019, USA
    Cancer Prev Res (Phila) 6:91-9. 2013

Detail Information

Publications27

  1. pmc Moving a randomized clinical trial into an observational cohort
    Phyllis J Goodman
    SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Clin Trials 10:131-42. 2013
    ....
  2. ncbi request reprint The prostate cancer prevention trial: design, biases and interpretation of study results
    Phyllis J Goodman
    Southwest Oncology Group Statistical Center, Seattle, Washington 98109 1024, USA
    J Urol 175:2234-42. 2006
    ..We describe the complexities of the study design of the PCPT and how they influenced the end point chosen, trial implementation, analysis and interpretation of the results...
  3. pmc Transition of a clinical trial into translational research: the prostate cancer prevention trial experience
    Phyllis J Goodman
    Fred Hutchinson Cancer Research Center, Seattle WA 98109, USA
    Cancer Prev Res (Phila) 3:1523-33. 2010
    ..We provide a framework for doing collaborative research in an international setting structured around a common theme of a clinical trial...
  4. ncbi request reprint Implementation of the Prostate Cancer Prevention Trial (PCPT)
    Phyllis J Goodman
    Southwest Oncology Group Statistical Center, M S M3 C102, 1100 Fairview Avenue North, Box 19024, Seattle, WA 98109 1024, USA
    Control Clin Trials 25:203-22. 2004
    ..We present an overview of the study design, details of the administrative structure of the study and a description of the successful implementation of the accrual phase...
  5. pmc Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach
    Mary W Redman
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Cancer Prev Res (Phila) 1:174-81. 2008
    ..Therefore, men undergoing regular prostate cancer screening or who express an interest in cancer prevention should be informed of the opportunity to take finasteride for preventing prostate cancer...
  6. ncbi request reprint Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial
    Zhihong Gong
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North M4 B402, Seattle, WA 98109 1024, USA
    Cancer Epidemiol Biomarkers Prev 15:1977-83. 2006
    ..Obesity increases the risk of high-grade but decreases the risk of low-grade prostate cancer, and this relationship is independent of the lower risk for prostate cancer among men with diabetes...
  7. pmc Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial
    Marian L Neuhouser
    Cancer Prevention Program, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Prostate 68:1477-86. 2008
    ....
  8. pmc Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial
    Alan R Kristal
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M4 B402, PO Box 19024, Seattle, WA 98109 1024, USA
    Am J Epidemiol 168:1416-24. 2008
    ..Genetic or environmental factors that affect the activity of 5-alpha-reductase may be important in the development of symptomatic BPH...
  9. pmc Associations of serum sex steroid hormone and 5α-androstane-3α,17β-diol glucuronide concentrations with prostate cancer risk among men treated with finasteride
    Alan R Kristal
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Cancer Epidemiol Biomarkers Prev 21:1823-32. 2012
    ..It also modestly increases serum testosterone (T), estrone (E(1)), and estradiol (E(2)). In this altered hormonal milieu, it is unknown whether serum concentrations of these hormones are associated with prostate cancer risk...
  10. pmc Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trial
    Marian L Neuhouser
    Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98019, USA
    Cancer Prev Res (Phila) 6:91-9. 2013
    ..Further research is needed to understand better the risk incurred by high IGFBP2 and whether androgen-suppressing agents such as finasteride influence aspects of IGFBP2 physiology relevant to prostate carcinogenesis...
  11. ncbi request reprint Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase
    Alan R Kristal
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Cancer 106:320-8. 2006
    ..The objective of this study was to examine whether demographic and lifestyle characteristics are associated with prostate-specific antigen (PSA) levels and the rate of PSA increase (PSA velocity)...
  12. ncbi request reprint Estimated impact of the Prostate Cancer Prevention Trial on population mortality
    Joseph M Unger
    Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Cancer 103:1375-80. 2005
    ..0% in the PCPT placebo arm vs. 11.9% in the PCPT finasteride arm). Whether the increased Gleason score was valid or was a histologic artifact is under investigation...
  13. ncbi request reprint Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials
    Catherine M Tangen
    Southwest Oncology Group Statistical Center, Seattle, Washington, USA
    J Urol 171:S64-7. 2004
    ..We briefly describe the purpose of phase II studies as a source of preliminary data for phase III prevention trials, and address statistical and other practical considerations for phase III prostate cancer prevention trials...
  14. ncbi request reprint Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial
    Ruth D Etzioni
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    J Urol 174:877-81. 2005
    ..We estimated the long-term effects of finasteride on PSA in men with and without a prostate cancer diagnosis at the end of the study...
  15. ncbi request reprint Biomarker-based methods for determining noncompliance in a prevention trial
    Donna K Pauler
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Control Clin Trials 23:675-85. 2002
    ..Our results indicate that simple absolute threshold monitoring rules perform just as well as more complicated rules that utilize the entire biomarker history...
  16. ncbi request reprint SELECT: the selenium and vitamin E cancer prevention trial
    Eric A Klein
    Section of Urologic Oncology, Department of Urology, Cleveland Clinic Foundation, Cleveland, OH, USA
    Urol Oncol 21:59-65. 2003
    ..SELECT is a randomized, prospective, double-blind study designed to determine if selenium and vitamin E can reduce the risk of prostate cancer among healthy men...
  17. ncbi request reprint The selenium and vitamin E cancer prevention trial
    Eric A Klein
    Section of Urologic Oncology, Urological Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, OH 44195, Cleveland, USA
    World J Urol 21:21-7. 2003
    ....
  18. ncbi request reprint The influence of finasteride on the development of prostate cancer
    Ian M Thompson
    University of Texas Health Science Center, San Antonio, USA
    N Engl J Med 349:215-24. 2003
    ..Finasteride, an inhibitor of 5alpha-reductase, inhibits the conversion of testosterone to dihydrotestosterone, the primary androgen in the prostate, and may reduce the risk of prostate cancer...
  19. ncbi request reprint Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter
    Ian M Thompson
    Division of Urology, Department of Surgery, University of Texas Health Science Center at San Antonio, San Antonio, Tex, USA
    N Engl J Med 350:2239-46. 2004
    ..We investigated the prevalence of prostate cancer among men in the Prostate Cancer Prevention Trial who had a PSA level of 4.0 ng per milliliter or less...
  20. ncbi request reprint Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
    Scott M Lippman
    The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Natl Cancer Inst 97:94-102. 2005
    ....
  21. ncbi request reprint Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, TX 78229, USA
    JAMA 294:66-70. 2005
    ..Three fourths of US men older than 50 years have been screened with prostate-specific antigen (PSA) for prostate cancer...
  22. ncbi request reprint Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial
    M Scott Lucia
    Department of Pathology, University of Colorado Denver and Health Sciences Center, 4200 E Ninth Ave, Box B 216, Denver, CO 80262, USA
    J Natl Cancer Inst 99:1375-83. 2007
    ..We assessed whether the increased high-grade prostate cancer associated with finasteride in the PCPT was due to finasteride's potential effects on tumor morphology or prostate size...
  23. ncbi request reprint Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
    J Clin Oncol 25:3076-81. 2007
    ..Using data from men in the finasteride group of the Prostate Cancer Prevention Trial (PCPT), we evaluated the impact of prostate-specific antigen (PSA) and other risk factors on the risk of prostate cancer...
  24. ncbi request reprint Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA
    J Urol 177:1749-52. 2007
    ..In the current study we report the impact of finasteride on digital rectal examination sensitivity and specificity...
  25. ncbi request reprint Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisited
    Eric A Klein
    Section of Urologic Oncology, Glickman Urological Institute, Cleveland, OH 44195, USA
    J Clin Oncol 23:7460-6. 2005
    ....
  26. ncbi request reprint Effect of finasteride on the sensitivity of PSA for detecting prostate cancer
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    J Natl Cancer Inst 98:1128-33. 2006
    ..We examined the impact of finasteride on the sensitivity and area under the receiver operating characteristic curve (AUC) of prostate-specific antigen (PSA) for detecting prostate cancer...
  27. ncbi request reprint Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center, San Antonio, TX 78229, USA
    J Natl Cancer Inst 98:529-34. 2006
    ..We used prostate biopsy data from men who participated in the Prostate Cancer Prevention Trial (PCPT) to develop a predictive model of prostate cancer...